


**Product Name** : IMU-935  
**Cat. No.** : PC-20040  
**CAS No.** : 2299252-72-3  
**Molecular Formula** : C<sub>22</sub>H<sub>18</sub>ClF<sub>4</sub>N<sub>5</sub>O<sub>2</sub>  
**Molecular Weight** : 495.86  
**Target** : ROR  
**Solubility** : 10 mM in DMSO



## Biological Activity

IMU-935 (Izumerogant, IMU935, IM105935) is a potent, selective and orally available inverse agonist / inhibitor of retinoic acid-related orphan receptor gamma (**ROR $\gamma$ t**) with IC<sub>50</sub> of 24 nM.

IMU-935 is shown to be a DHODH Inhibitor with an IC<sub>50</sub> of 240 nM.

IMU-935 demonstrates synergistic inhibition of the secretion of IL-17A, IL-17F and IFN $\gamma$  with IC<sub>50</sub> concentrations of 3-5 nM tested in stimulated human lymphocytes.

IMU-935 inhibits Th17 differentiation of murine cells (IC<sub>50</sub>=135 nM), and inhibits IL-17F production from stimulated human PBMCs with IC<sub>50</sub> of 2-4 nM.

IMU-935 demonstrates a strong inhibition of GM-CSF, IL-17A, IL-17F and IL-22 in inflamed human skin model (skin punches from human healthy volunteers).

IMU-935 inhibits Th17 differentiation and reduced EAE severity without affecting thymocyte development by selectively targeting the ROR $\gamma$ t-CBF $\beta$  interaction in Th17 cells but not in thymocytes.

## References

- Patent WO2019048541. 2019-03-14.
- Wu H, et al. *J Clin Invest*. 2026 Jan 2;136(1):e185942.

**Caution: Product has not been fully validated for medical applications. Lab Use Only!**

E-mail: tech@probechem.com